Skip to main content
. 2023 Jan 18;15(3):600. doi: 10.3390/cancers15030600

Figure 3.

Figure 3

Forest plot of the safety of neoadjuvant immune checkpoint inhibitors in resectable hepatocellular carcinoma. (A) Grade 3–4 TRAEs, (B) Surgical delay rate. ICIs: immune checkpoint inhibitors. TRAEs: treatment-related adverse events [30,31,32,33,34,35,36,37,38].